Do not suffer from hepatitis B chemotherapy!

The Hong Kong Medical School study found that 20% of people with hepatitis B lymphoma patients hidden in the receiving chemotherapy are more prone hepatitis B-related diseases, or even lead to liver failure and death. The Hong Kong Medical School study found that 20% of people with hepatitis B lymphoma patients hidden in the receiving chemotherapy are more prone hepatitis B-related diseases, or even lead to liver failure and death.

They suggested that in cancer patients undergoing chemotherapy, should conduct more sophisticated hepatitis B virus gene tests to determine whether they are “carriers.”

The study by the University of Hong Kong Li Ka Shing Faculty of Medicine in science between 1998 and 2005, a total of study 244 are receiving chemotherapy for lymphoma patients, in which 57 people, or about 20% of the “hidden hepatitis B carriers “The traditional protein test also found to have failed to detect hepatitis B virus genes through the real-time polymerization chain reaction (PCR), to determine they are hepatitis B carriers. These 57 people undergoing chemotherapy, eight of whom trigger hepatitis B-related diseases, of which three were due to liver failure and death.

Within the University of Hong Kong, an associate professor of science, Hong Kong, there are 700,000 people are carriers of hepatitis B, and about 20% are “hidden” and the carriers themselves do not know.

The Department of the Hong Kong University of Science Chair Professor explained that the chemotherapy or steroid treatment to the Human Immunodeficiency will decline, unable to inhibit hepatitis B virus, hepatitis B disease so that more prone to or relapse, and even liver failure and death.

Traditional protein has not been fully tested to identify carriers of hepatitis B, hepatitis B protein test test is an outdated concept, the PCR method is more accurate; fact more than lymphoma patients, all in need of chemotherapy, and I wonder if he is a Hepatitis B carriers cancer patients in chemotherapy, are more likely suffering from hepatitis B-related diseases, or even lead to liver failure and death.

Recommendations patients undergoing chemotherapy, should receive PCR to determine whether hepatitis B carriers, “doctors should closely monitor patients with hepatitis B in the case after receiving chemotherapy, if found to be disease, treatment should be imposed as early as possible.” He said that, at present, some private laboratories and public hospitals can carry out PCR testing.

It is reported that this study is the first study found hidden hepatitis B patients undergoing chemotherapy and the relationship between the results of the study in July 2006 published in the international medical journal “Gastroenterology.”

Hepatitis B virus resistance and control strategies

Nucleoside (acid) analogues is currently Clinical important in the treatment of hepatitis B antiviral drugs, such drugs through direct inhibition of HBV DNA replication, thereby improving the liver histological lesions, retard the progress of hepatitis B disease, reduce complications from occurring. But long-term treatment in HIV drug resistance is such a common issue facing. The anti-viral drug resistance can lead to virologic rebound and worsening of the illness. The United States NIH in 2006 hepatitis B treatment session (Lok A, et al. Program of the 2006 management of Hepatitis B virus meeting, 2006), and in 2006 the United States Institute of digestion by some experts of the “diagnosis and treatment of hepatitis B norms” (Keeffe E, et al. Clin Gastroenterol Hepatol, 2006), the virus was agreed that the definition of resistance (Figure 1): genotype resistance is direct sequencing of PCR products used Determination HBV polymerase mutation is resistant phenotype in vitro cell culture or activity proved resistant variation; virology rebound treatment refers to treatment of HBV DNA than the minimum value increased ≥ 1 log; Health rebound it refers to the chemical reached after initial response to treatment ALT increased, which gene usually first-resistant rebound in virology, and virology rebound and rebound ahead of the chemical hygiene.

HBV clinical implications of drug resistance

Drug resistance is the long-term anti - hepatitis B virus treatment of serious clinical problem. The HBV nucleoside (acid) analogues resistance after clinical consequences of the following: can lead to virologic rebound, the Health and chemical backlash occurred serology recurrence; liver disease progress, such as possible liver disease and acute exacerbation of liver failure, liver transplantation needs or died of liver transplantation due to hepatitis B antiviral drug resistance and failure. Follow-resistant virus can also affect the anti-virus treatment efficacy so that the effect of poor follow-up or treatment resistant rate increased resistance also may lead to the spread of the virus.

Liaw, and so the studies show that lamivudine - resistant mutations can lead to long-term treatment of patients with cirrhosis and decreased disease progress. Another lamivudine (Liaw et al. N Eng J Med, 2004) long-term treatment of patients with liver cirrhosis, according to obtain sustained virologic response was significantly higher than that the survival rate of patients with drug resistance YMDD mutation and no response was virology the patients (P = 0.001), thereby reducing the occurrence of resistance suggested that the effect of a decrease of survival time in patients with liver cirrhosis. Hepatitis B treatment methods>>>

Potent inhibition of virus barrier and the impact on resistance

Colonno annual meeting in 2006 AASLD mentioned in the report, when the virus completely inhibited when, on the one hand drug-sensitive strains were the maximum inhibition, on the other hand resistant mutant viruses have also decreased significantly when the virus is not completely inhibited, the virus also in reproduction, to increase the likelihood of drug resistance mutations. Potent anti-viral drug resistant virus with the “high-barrier,” the first is that the pharmacokinetics barriers that drugs reach the target organ with the concentration required for the concentration of virus inhibition ratio, drugs reach the target organ concentrations higher inhibit virus the lower the concentration required, the greater the ratio, in a “high pharmacokinetics barriers”; Second, the high number of barriers need mutant gene loci simultaneously can produce resistance; 3 refers to the viability of mutant strain of the virus.

The diagnosis and monitoring of drug resistance

American Institute in 2006 released to digest the diagnosis and treatment of hepatitis B virus resistance to the standardized diagnostic criteria: PCR determination that the level of serum HBV DNA at the lowest level in more treatment increased ≥ 1 log, can be identified as virology rebound. The proposed treatment standards for acceptance should lamivudine - treated patients every 3 to 6 months to monitor 1st; adefovir dipivoxil or entecavir for treatment after one year, every six months should be monitoring 1st; on the progress of the liver patients should be monitored on a regular basis, that is, every three months to monitor the 1st. Currently in clinical and laboratory monitoring widely used by the virus resistant HBV DNA methods have rebounded nucleic acid hybridization and PCR method, the higher the sensitivity of the method can be more resistant to earlier monitoring. Foreign resistant genotype detection method for INNO - LiPA HBV DR2 and PCR direct sequencing, the former high sensitivity, but can only detect the known resistance gene loci, the kit has been used in clinical latter sensitivity lower, but can detect known and emerging resistance gene loci, mainly used for laboratory research.

The current HBV nucleoside (acid) analogues resistance characteristics

At present both in vitro and in vivo experiments have proved that with the resistance of the P gene variation, different nucleoside (acid) analogues resistant strains of variation is not consistent sites (Figure 2), such as lamivudine resistance-associated point mutations M204V / I, L180M, and other adefovir related mutation point for N236T, for the Beef as M204I, that is to say, the virus only need a bit mutation can occur resistance to these drugs, and a TU entecavir virus rebound need L180M and M204I / V + T184 or S202 or M250’s three-point mutation, said Mingen entecavir resistance genes with high barriers; another lead TU entecavir resistance in three sites mutation, including two lamivudine resistance mutations, that is to say the TU entecavir resistance must be built on the basis of lamivudine resistance, lamivudine therapy can elect lamivudine - resistant point mutations can also elect of entecavir for resistance mutations.

Lamivudine treatment five years resistance rates close to 70 percent adefovir treatment appeared resistant to lamivudine time later, but for five years, HBeAg-negative patients with primary drug resistance genotype rate was 29 percent, , HBeAg positive patients resistant virus led to the rebound rate was 20%; than stavudine for the treatment for one year, the initial treatment of patients with resistance rebound rate of 4.4% (HBeAg positive), 2.7% (HBeAg negative), 2, when it rose to 21.6 percent, 8.6 percent.

TU entecavir resistance data for three years, three years for a total of three cases of newly diagnosed patients in TU entecavir resistance mutations, these three patients in the baseline at the existence of lamivudine - resistant mutations or TU for the Kahuijia lamivudine - resistant mutations, three years because of resistance led to the virology rebound <1% (Table 1). The reasons for the low rate of drug resistance attributed to TU first entecavir have potent antiviral activity, followed by the resistance gene with high barriers need three sites at the same time can produce drug resistance mutations.

Resistance prevention

Based on the occurrence of HIV drug resistance and the degree of inhibition virus closely related to viral load can be reduced to the level of uncertainty in the resistance may be, it should use potent antiviral drugs, rapid and sustained inhibit viral load to the level of unpredictability At the same time we should select high-resistance gene barriers antiviral drugs; In addition, the increase in compliance, early response is not satisfactory and timely manner to avoid dressing change sequential single-drug treatment, but also help to prevent the occurrence of resistance.

The handling of drug resistance

After emerging resistant virus usually has the following approach: stop current therapy; continue the current treatment; plus another antiviral drugs; to switch to another anti-viral drug. Now that the current treatment and to stop the current treatment, have been reported in the literature can cause acute exacerbation of hepatitis and even liver compensated and should not be used. The current recommended after two methods, the specific approach: ① in lamivudine - resistant, it can increase or switch to adefovir dipivoxil, or switch to TU entecavir; ② adefovir dipivoxil resistance , plus lamivudine or can switch to TU entecavir; ③ TU entecavir resistance, it can increase or alone adefovir dipivoxil. How drug hepatitis patients>>

Summary

Antiviral drug resistance in the long-term treatment of Hepatitis B is a major clinical problem, virus resistance will lead to serious clinical outcomes, and the need for close monitoring. TU entecavir (Bo Road), is the lowest incidence of drug resistance nucleoside analogues. Nucleoside analogues in the initial treatment of patients through the use of potent antiviral drugs, the use of high-resistance gene barriers antiviral drugs, and enhance the patient’s compliance, HBV resistance can be reduced time delay and resistance rates. When the resistance occurred, it should consider the use of potent antiretroviral therapy or in combination.

Successful cultivation in vitro Hepatitis C virus

According to the latest issue of “American pathology journals” (The American Journal of Pathology), a paper that scientists have broken through the bottleneck of patients separated from the liver cells (hepatocytes), together with the patient’s serum (Serum) , successfully cultured in vitro Hepatitis C virus (Hepatitis C Virus).

Clinical lead to liver inflammation, cirrhosis, liver cancer and liver transplant led to the needs of the main reasons is that hepatitis C virus infection, according to international statistics related health units, the global population of about 170 million, infection this is a threat of disease, hepatitis C virus but the most serious problem is that the virus no way in vitro, resulting in drug research and development progress has been rather slow.

Kingston University School of Medicine, St. Dr. Nelson Fausto of the research team, the use of human fetal liver cells (hepatocyte), the development of the hepatitis C virus in vitro system, confirmed hepatitis C virus can indeed in Petri dishes, a copy survival 2, the researchers then infected with different strains of hepatitis C virus in the serum of patients, the virus added to the medium, confirming that the new generation of virus particles, not only in the replication cycle of infection of the liver with a cycle, and even the freshmen the virus particles, but also healthy liver cells infected with the capacity.

Now researchers in-depth analysis of this newly developed virus cultivation systems, and different strains of hepatitis C virus between the relationship, and we hope to really control this special virus activities of the secret to accelerate drug development.

The best treatment of hepatitis B

Specific active immunotherapy is the best treatment of hepatitis B

Hepatitis B treatment methods over its few, why unique “specific active immunotherapy,” known as 2004 the latest hepatitis B treatment methods? Summing up all the evaluations, the following main points:

1, specific immunotherapy is based initiative “of hepatitis B virus removal Doctrine,” developed by the hepatitis B therapy.

As early as in 1975, world renowned liver expert Professor raised the famous “liver virus removal doctrine.” The doctrine, hepatitis B treatment, the key is to eliminate hepatitis B virus, hepatitis B virus has not been completely removed, it can not be said to have been cured of hepatitis B. Therefore, the treatment of hepatitis B, the most critical thing is to choose to eliminate hepatitis B virus drugs. “Specific Active Immunotherapy hepatitis B,” according to “hepatitis B virus removal Doctrine,” after 10 years of experiment and developed the effective removal of the Liver HBV therapy.

2, hepatitis B specific active immunotherapy can effectively eliminate hepatitis B virus

More than one year in patients with chronic hepatitis B liver hepatitis B virus cells has been the depth of erosion, and constantly copying and reproduction, which bring great trouble to treatment. On the one hand, due to the protection of their own liver, liver cells do not produce the hepatitis B virus immune response, which is in a period of hepatitis B virus immune tolerance, which are difficult to cure hepatitis B is past the fundamental issue. Conventional drugs in the liver cells fail to recognize the hepatitis B virus, is not removed; On the other hand, if the direct killing of hepatitis B virus, it will also damage or even kill their combined liver cells, causing liver damage.

Specific active immunotherapy overcome the shortcomings of traditional treatment, in a targeted manner to break immune tolerance to hepatitis B virus, stimulate the body’s immune response, so that the body itself produce high concentration of endogenous interferon, and without harm its own premise, complete removal of hepatitis B virus. Therefore, the solution to this “dilemma” problem shows the incomparable superiority. Specific active immunotherapy that the body produce high concentration of endogenous interferon, hepatitis B virus has a strong ability to identify clearly and fully in vivo activation of T lymphocytes, activate liver own immune system, thus ” drug and use immunity, promoting drug and immunity “effect. Inside and outside with a two-way, complete clearance of hepatitis B virus, repair damaged liver cells, and to promote new cell growth.

3, clinical cure, more convincing

Specific active immunotherapy, in the international symposium on viral hepatitis from all over the world received national recognition liver disease authoritative experts and applications. This therapy has been designated hospitals in clinical trials base in a three-year clinical trials. The results show that: specific active immunization initiative therapy for chronic liver disease total effective rate was 98.8%, the cure rate was 70.3%. From 2001 to 2003, only a year’s time, the treatment of Hepatitis B in China under the jurisdiction of the Committee on base to various clinical collaboration has ruled tens of thousands of hepatitis B patients. These include cirrhosis, liver ascites, alcoholic liver, fatty liver patients, the experts on the effect of various patients throughout tracking. After more than a year of treatment, and basic are very good results, and most of the patients were cured.

Chronic hepatitis B is the ultimate goal of treatment:

First, remove viruses;

Second, prevent or delay the occurrence of hepatic fibrosis, and prevent further deterioration of liver cirrhosis and hepatocellular carcinoma.

A particular emphasis here is: Many people believe that the fundamental purpose of the treatment of hepatitis B is “negative” In fact, this view is not correct, the process is negative, this is not objective. Anti-viral treatment is the main purpose: inhibition of hepatitis B virus DNA replication, to prevent hepatitis B virus progress to prevent hepatitis B develop into liver cirrhosis or liver cancer.

B, hepatitis B market the drug in the treatment of all kinds, some patients with small cheap greed, I believe false advertising, leading to blind patients with medication is not only not an ideal treatment, squandering wronged money, or even add to the burden on the liver, and further lead to liver disease,

C, from the overall anti-virus treatment therapy speaking, the most scientific method of treatment by the United States, Japan, Britain, China, and other common liver disease experts, the study “Breaking the hepatitis B virus immune tolerance therapy” (that is, specific initiative immunotherapy). For this reason, China Hepatitis B Treatment Research Council set up throughout the country more than 100 clinical liver disease collaboration bases, and comprehensive application of the latest therapies - specific active hepatitis B immune therapy, it can break immune tolerance, thereby enabling the body to hepatitis B play specific immune function, to complete the treatment of hepatitis B purposes.

D, adopted in Integrative Medicine symptomatic treatment (treatment of liver fibrosis), the body in time to improve the symptoms and repair liver function, and promote liver cells hygiene, a timely and effective manner to prevent the formation of cirrhosis or liver cancer.

The treatment of liver disease must be informal to the formal hospital for treatment, or else easily relapse, not easily cured.

Detection of HBV genotype help determine efficacy of lamivudine

Tokyo Toranomon Hospital Kobayashi, and other reports, in patients with hepatitis B virus genotype B, for the response to antiviral therapy lamivudine best, and worst A genotype reaction. [J Med Virol 2006,78 (10): 1276]

Kobayashi, and other studies were included in the 502 cases of hepatitis B virus (HBV) infection long-term, 15 cases of infection of HBV genotypes A, 38 cases of B genotypes, and the remaining 449 cases for C genotype, age three groups of infected persons median 37-year-old, 47-year-old and 44-year-old. Comparing more than one year of lamivudine treatment on the three groups of infected persons.

The results showed that, A genotype of hepatitis B virus e antigen (HBeAg) - positive rate was significantly higher than B, C genotype (respectively 73%, 21% and 56%, P <0.001), the former HBV DNA was also significantly higher in the latter two (per milliliter of several genome equivalents were 8.6,6.5 and 6.5, P = 0.024). significantly higher than that of the latter two (P = 0.0001, P = 0.023). A genotype both HBeAg positive or not, leads YMDD mutation rate is higher than B, C genotype (P = 0.037, P = 0.003). Cox proportional hazards model analysis showed that genotype HBeAg positive and A YMDD mutation to be there.

Research Tip: Detection of HBV genotype, in patients with chronic hepatitis B help predict long-term treatment of lamivudine and the response of the occurrence of YMDD mutation. The weaker response to treatment in patients with genotype A may consider the adefovir dipivoxil treatment, because regardless of whether patients with HBeAg positive, which all have good effect and difficult to lead resistance mutations.

Long-acting interferon charged with hepatitis B treatment

Treatment of hepatitis B antiviral efficacy with limited variability of the virus how to solve? China had approximately 130 million hepatitis B virus carriers, but the anti - hepatitis B virus treatment rarely. Treatment of hepatitis B antiviral efficacy with limited variability of the virus how to solve? Reporter from the recent conclusion of the Hong Kong - Shanghai 2005 medical seminar was informed that the new areas, these medical problems are being tackled by the two experts, was using stem cell technology treatment of Myocardial Infarction, interferon with the antiviral hepatitis B and other new governance progress.

Governance MI grow to their cells “good” Heart

A myocardial infarction patients, even if the rescue success, and often accompanied by the weakening heart function, from bed-ridden. While traditional medical methods can only heart transplant patients, to improve quality of life, but from the heart allograft transplantation possible and then have to face the rejection, and even lead to surgery failed.

Heart Hospital of Zhongshan Medical Director, Shanghai Institute of Cardiovascular Disease by Professor Changge Junbo, the myocardial cells is different from adult normal cells, and damaged it can not be renewable only scarring, acute myocardial infarction after easily lead to the period heart failure. Two years ago, Zhongshan Hospital began to stem cell research, from taking part in the human bone marrow, from mononuclear cells isolated from the cardiac stem cells injected through the catheter into the patient’s heart infarction occurred in the site, sprouted integrity of the “good” heart. This is the first domestic use stem cell technology to the treatment of myocardial infarction.

Recently, they patients on 60 number for myocardial infarction clinical trials found that some patients after stem cell transplantation in cardiac function shown a turn for the better. Various indicators, including heart failure symptoms, such as angry clinical symptoms have improved. As stem cell transplantation by the admission of their own bone marrow from patients, a relatively small reaction. “But how is the role of stem cells, specific principles and mechanisms are still not clear enough, then we need to do a large-scale clinical trials before they are able to promote stem cell technology,” Ge Junbo said.

Long-acting interferon charged with hepatitis B treatment

According to the Chinese University of Hong Kong vice president of medical and drug SUNG head of the Department of professor said, China had approximately 130 million hepatitis B virus carriers, but the anti - hepatitis B virus treatment rarely. The traditional treatment is the use of antiviral drugs alone, but anti-viral drug lamivudine only a long-term, but limited efficacy of lamivudine, once the medication to stop after 12, most patients will relapse, medication 2001 after the hepatitis B virus may also begin variation, thereby reducing effects.

Chinese University of Hong Kong’s latest experimental results show that the public, together with interferon therapy with lamivudine alone antiviral effect than good, according to 100 patients controlled trials, a year cure rate from 15% to 30-35% , that is, one year after stopping treatment for six months after the lower the probability of relapse by more than half. But if heavy hepatitis patients, or poor liver function, it must first be used lamivudine liver function restored to a certain extent can we use lamivudine with interferon treatment. Because interferon generally higher cost, Chinese University of Hong Kong to replace the use of long-acting interferon, injected once a week only, the whole treatment costs about 40,000 to 50,000 yuan a year.

The best time for hepatitis B treatment

Hepatitis B immune to the attention of governance should be carried out in stages in accordance with the immune response diagnosis and treatment can reduce the blindness and randomness, and markedly increase clinical efficacy. Experts say immunotherapy combined with antiviral treatment of hepatitis B is a direction.

China is a high incidence area of hepatitis B virus infection, hepatitis B virus carrying crowd rate of 9.75 percent, about 120 million people, patients with chronic hepatitis B about 30 million people. Recent studies show that attention should be paid to governance HBV immunity, the immune response should be carried out in stages in accordance with the diagnosis and treatment can reduce the blindness and randomness, and markedly increase clinical efficacy. This reporter recently interviewed for the team.

Hepatitis B also talk about timing rule

The so-called “three-in-one” refers to treatment programs specific immune therapy, and non-specific immunotherapy joint use of antiviral drugs, also known as “cocktail therapy.” The specific immune therapy refers to a specific cell-mediated immune response of hepatitis B vaccine, including the treatment of non-specific immune multicomponent thymosin, pHGF, interferon and the antiviral therapeutic alliance Hepuding addition, the new drug adefovir is about to enter clinical and immunological therapy combined with antiviral drugs will be the future direction of a hepatitis B treatment.

After clinical practice in recent years shows that the immune response carried out in stages in accordance with the diagnosis and treatment can reduce the blindness and randomness, and markedly increase clinical efficacy.

Elevated transaminase “li” and “disadvantages”

According to the research at home and abroad, can be divided into chronic hepatitis B immune tolerance period, the immune clearance phase, the virus residual period. In the course of treatment or repeatedly elevated transaminase abnormalities should be divided into two dialectical perspective to analyze their “profit” and “disadvantages”, suggested that elevated transaminase in the liver cell injury inflammation, but also shows that the immune system has been negative defense to active defense, and this time happens to be a good anti-virus treatment time, but are often neglected patients and doctors. Through a large number of immune regulation of endogenous cytokines, coupled with the antiviral drugs, will play an effective and efficient. Residues of chronic hepatitis B virus most likely to be ignored, Its mechanism may inhibit or removal of the nucleus of the hepatitis B virus replication template, should actively to block its treatment to liver cirrhosis and primary liver cancer development, which is of great clinical significance.

Knowledge

Immune Tolerance period: that the immune system of patients infected with the virus do not have a specific immune response, high virus replication and expression (HBV DNA and e antigen significantly higher), alanine aminotransferase normal, significantly lower specific cell function.

Immunization clearance period: activation of the immune system in the state (immunity higher), characterized by: ALT significantly higher (100 units above), but quantitative and e antigen of hepatitis B virus DNA still high moderate levels. Specific immunity for the middle level and above increased.

Virus residual period: that virus replication is already in a low-level replication or reproduction (non-active) state. Its characteristics are both hepatitis B小三阳, if the low level of virus replication, normal or low immunity, GPT normal or mildly elevated, the state should actively such treatment.

Stop Hepatitis into liver cancer

general relatively short, the need for 8-9 years. chronic active hepatitis of a machine will be launched into cirrhosis, the need of life through drug treatment and conditioning to reduce or control disease development. “Beijing Public Security Bureau’s Wu Wen TCM hospitals doctors advise patients with hepatitis soldiers, attention to health care and treatment, 10% from liver disease to liver cancer.

Doctors reminded Wen said, which must be under the guidance of professional medical treatment, and put forward the following suggestions:

1, cautiously uses drugs, in particular should not blindly raise immunity using some drugs.

2, the intermediate metabolite of alcohol are more definite liver toxicity, all drinks containing alcohol are not drinking (including wine). After drinking wine in the gastrointestinal tract quickly been absorbed, about 90 per cent of the alcohol content (ethanol) in liver metabolism, which are directly stimulate ethanol, the damage to the liver toxicity of cells, liver cells can degeneration and necrosis . The toxic effects of ethanol metabolism and detoxification of normal liver function, and lead to serious liver injury and alcoholic cirrhosis. Therefore patients with liver diseases, Temperance is the basic requirement of self-convalescence.

3, attention to diet and nutrition. There are many patients with chronic liver disease of the digestive system diseases, digestion and absorption capacity is rather poor, must pay attention to strengthening nutrition. To improve liver disease patients on the utilization of nutrients, cooking, we should pay attention to. Patients with liver disease, like to eat rice. Cook rice porridge and alkali practice to avoid, but also eat less fried food, because long-term eating fried foods easily with cancer. Moldy food, avoid consumption. Dynamic, vegetable oil and Kazakhstan are unsuitable for consumption after La Salle flavor, these foods can trigger cancer.

4, reasonable rest. Patients with chronic hepatitis must ensure that the full day of rest, but we must not blindly rest, in whatever circumstances, be appropriate to do some activities. What merits attention is that absolutely can not be engaged in heavy physical labor.

Stay up late is out, every night, in addition to guarantees 7-8 hours of sleep, preferably at noon morning for half an hour. In addition, long-term use eyes, and often change will affect liver function, therefore, is to eliminate eyestrain, cross-work law can be achieved through active rest.

5, mediation taste. To avoid depression, anger and other negative emotions stimulation. Over-excited, angry, directly or indirectly, will hurt the liver, and particularly to prevent anger. Only by maintaining a happy mood, and to help the rehabilitation of liver disease.

6, to warm cold work. In patients with liver disease in a sick body immune imbalance, if cold, fever will add to liver injury, so, and particularly to prevent a cold, the temperature change at any time to change clothes.

To avoid recurrence of liver disease

Some patients leave the hospital one that everything is all right now on, pay no attention to recuperate, with the result that illness relapse, deteriorate, leading to irreversible results. In fact, the liver pathology clinical indicators than repair resume slowly. That is to say, when the disease tends to restore serum transaminase, and other indicators have normal liver function, the liver tissue inflammation but. Clinical cure the various indicators of the standard follow-up for one year without abnormal changes, hepatitis B surface antigen negative requested, to be cured of acute hepatitis. The basic cure for chronic hepatitis after discharge to observe more than two years, the sustained and stable condition and will rise to normal workers to be cured. In the early period of rehabilitation work and engaged in a heavy dramatic movement, is not appropriate.

Second, prevention of influenza infection and

Performance of the clinical experience of many years, many patients with liver disease usually is not pay attention to some details in daily life, such as changes in the well-being of the weather clothing, diet and health neglect, the only condition significantly heavier. Patients with liver disease in the course of illness is a long illness is imaginary body, and all kinds of viruses, bacteria, fungi and other microbial pathogens often take advantage of. Thus patients with liver diseases often associated with a cold and pharyngitis, furuncle swollen skin, bronchitis, pneumonia, pleurisy, urinary tract infections, even endotoxemia, and other diseases, so that the already static or tend to cure diseases and deteriorating again , in patients with daily diet, hygiene, and many should be more careful. Physical exercise should be appropriately with changes in temperature change clothes.

Third, diligence review

Generally speaking acute hepatitis patients discharged patients each half of the first month of reexamination 1st, 2nd all normal can be 1-2 months reexamination 1, six months after every three months reexamination 1st. The asymptomatic carriers of hepatitis B surface antigen (ASC) annual reexamination 1st. Special circumstances can always check.

Effective treatment of hepatitis B

Prevention of Hepatitis B can not be overlooked, generally speaking, including five aspects of prevention … how to treat hepatitis B?

Usually, hepatitis B treatment methods include:

• The use of interferon. For patients with the use of interferon injections is generally taken the form. For most patients, the treatment probably last for four months.

• using drugs: lamivudine (Lamivudine). Oral, once a day. Treatment is usually one year.

• medication: adefovir dipivoxil (adefovir dipivoxil). Oral, once a day. Treatment is usually one year.

• surgery. With the passage of time, may result in hepatitis B liver to stop functioning, this time, you will need for a new liver has. Such as liver transplant surgery, the surgery is the removal of the old liver damage, and then from donors on a new health into the liver.

How do I protect themselves against hepatitis B harm?

You can hepatitis B vaccine inoculation

Vaccination is a kind of medicine, the health of time when you vaccination, you can enhance immunity, away from disease. Vaccines to protect your body to prevent some viruses (such as hepatitis B virus) invasion.

Hepatitis B vaccine should be vaccinated three times in general, all children should be vaccinated, babies born after the 12-hour period should be vaccinated first needle hepatitis B vaccine in 1-2 months or so to the second inoculation needle, and then 6 — 18, the third time inoculation needle.

Some older children and adults also need hepatitis B vaccine program. They will be six months inoculated three vaccines. The hepatitis B vaccine has not been vaccinated children should be vaccinated immediately to the hospital.

You need three vaccines to protect himself. When you travel to other countries, before proceeding to ensure that you End three hepatitis B vaccine inoculation. If you have a no vaccine inoculation, then immediately call your doctor or hospital for appointments. Because the vaccine can protect you, you against hepatitis B virus attacks.

Follow these recommendations, you can protect yourself and others, to stay away from hepatitis B!

1) If the work to contact with blood, please wear gloves, stay away from hepatitis B virus.

2) Do not use with any person with a syringe

3) sex must wear condoms when

4) Do not use in patients with hepatitis B toothbrushes, razors and other possible items stained with blood

5) up at the tattoo must use clean, sterilized a tool.